DÄ internationalArchiveReferences
References

Review article

The Treatment of Colorectal Carcinoma With Monoclonal Antibodies - The Importance of KRAS Mutation Analysis and EGFR Status

Dtsch Arztebl Int 2009; 106(12): 202-6. DOI: 10.3238/arztebl.2009.0202

Stintzing, S; Heinemann, V; Jung, A; Moosmann, N; Hiddemann, W; Kirchner, T

1. Cunningham D et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–45. MEDLINE
2. Mayer A et al.: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454–60. MEDLINE
3. Nicholson RI, Gee JM, Harper ME: EGFR and cancer prognosis. Eur J Cancer 2001; 37: 9–15. MEDLINE
4. Saltz LB et al.: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201–8. MEDLINE
5. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787–99. MEDLINE
6. Bos JL et al.: Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293–7. MEDLINE
7. Finkelstein SD et al.: Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993; 71: 3827–38. MEDLINE
8. Khosravi-Far R and CJ: The Ras signal transduction pathway. Cancer Metastasis Rev 1994; 13: 67–89. MEDLINE
9. Boughdady IS et al.: K-ras gene mutations in adenomas and carcinomas of the colon. Surg Oncol 1992; 1: 275–82. MEDLINE
10. Aaltonen LA et al.: Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812–6. MEDLINE
11. Oliveira C et al.: Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13: 2303–11. MEDLINE
12. Bazan V et al.: Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann Oncol 2005; 16: 50–5. MEDLINE
13. Amado RG et al.: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 6: 1626–34. MEDLINE
14. Dietel M et al.: Molecular pathologic KRAS mutation analysis: a prerequisite of effective antibody treatment for metastasized colorectal cancer. Chirurg 2008; 79: 576–9. MEDLINE
15. Esteller M et al.: K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19: 299–304. MEDLINE
16. Andreyev HJ et al.: Kirsten ras mutations in patients with colorectal cancer: the multicenter „RASCAL“ study. J Natl Cancer Inst 1998; 90: 675–84. MEDLINE
17. Dix BR et al.: The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 1994; 59: 747–51. MEDLINE
18. Karapetis CS et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757–65. MEDLINE
19. Lievre A et al.: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374–9. MEDLINE
20. De Roock W et al.: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508–15. MEDLINE
21. Cappuzzo F et al.: Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer 2008; 99: 83–9. MEDLINE
22. Di Fiore F et al.: Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166–9. MEDLINE
23. Khambata-Ford S et al.: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230–7. MEDLINE
24. di Nicolantonio F et al.: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705–12. MEDLINE
25. Ince WL et al.: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005; 97: 981–9. MEDLINE